Showing results (191-200 of 208) with videos related to
Sort By:
Pageof 21
Epigenetics|May 5, 2011
Aberrant TGFβ/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancerKun-Tu Yeh, Tze-Ho Chen, Hui-Wen Yang, et al.Journal of Cellular Biochemistry|April 20, 2021
Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA-1 regulationVan T Hoang, Margarite D Matossian, Jacqueline La, et al.Proceedings of the National Academy of Sciences of the United States of America|December 2, 2020
Targeting progesterone signaling prevents metastatic ovarian cancerOlga Kim, Eun Young Park, Sun Young Kwon, et al.Laboratory Investigation; a Journal of Technical Methods and Pathology|January 13, 2010
Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancerJian-Liang Chou, Her-Young Su, Lin-Yu Chen, et al.Anti-Cancer Drugs|August 16, 2020
A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple-negative breast cancer to identify targetable signaling pathwaysMargarite D Matossian, Hope E Burks, Steven Elliott, et al.Frontiers in Oncology|August 28, 2020
ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast CancerVan T Hoang, Margarite D Matossian, Deniz A Ucar, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2019
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian CancerAmit M Oza, Ursula A Matulonis, Angeles Alvarez Secord, et al.Nature Reviews. Cancer|September 24, 2011
Rethinking ovarian cancer: recommendations for improving outcomesSebastian Vaughan, Jermaine I Coward, Robert C Bast, et al.Journal of the National Cancer Institute|March 17, 2021
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer SurvivalLari Wenzel, Kathryn Osann, Chelsea McKinney, et al.Plos Genetics|June 5, 2020
In vivo modeling of metastatic human high-grade serous ovarian cancer in miceOlga Kim, Eun Young Park, David L Klinkebiel, et al.Pageof 21